X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (100103) 100103
Newsletter (8492) 8492
Publication (5702) 5702
Newspaper Article (5195) 5195
Book Review (1251) 1251
Book Chapter (609) 609
Magazine Article (379) 379
Book / eBook (254) 254
Trade Publication Article (175) 175
Conference Proceeding (120) 120
Web Resource (75) 75
Dissertation (52) 52
Reference (33) 33
Government Document (14) 14
Data Set (11) 11
Paper (11) 11
Report (9) 9
Transcript (5) 5
Journal / eJournal (3) 3
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (74466) 74466
thrombosis (54991) 54991
male (40047) 40047
female (38906) 38906
index medicus (34756) 34756
middle aged (28728) 28728
aged (22430) 22430
adult (22028) 22028
blood clot (17557) 17557
risk factors (16498) 16498
hematology (13965) 13965
treatment outcome (13660) 13660
peripheral vascular disease (13640) 13640
cardiac & cardiovascular systems (12642) 12642
surgery (12203) 12203
anticoagulants - therapeutic use (11392) 11392
thrombosis - etiology (10664) 10664
thromboembolism (10443) 10443
anticoagulants (9708) 9708
research (9423) 9423
animals (9109) 9109
care and treatment (8307) 8307
venous thrombosis (8260) 8260
thrombosis - drug therapy (7832) 7832
retrospective studies (7748) 7748
time factors (7299) 7299
aged, 80 and over (7050) 7050
venous thromboembolism (7010) 7010
medicine, general & internal (6571) 6571
deep-vein thrombosis (6407) 6407
prevention (6298) 6298
drug therapy (6250) 6250
stents (6226) 6226
therapy (6214) 6214
risk (6175) 6175
patients (6126) 6126
adolescent (6066) 6066
diagnosis (5949) 5949
thrombosis - prevention & control (5757) 5757
follow-up studies (5744) 5744
analysis (5459) 5459
stroke (5425) 5425
mortality (5366) 5366
medicine & public health (5351) 5351
prospective studies (5203) 5203
management (5181) 5181
pulmonary embolism (5138) 5138
health aspects (5010) 5010
abridged index medicus (4711) 4711
venous thrombosis - etiology (4651) 4651
medical research (4580) 4580
heparin (4558) 4558
fibrinolytic agents - therapeutic use (4451) 4451
disease (4407) 4407
cancer (4326) 4326
thrombolytic therapy (4297) 4297
cardiology (4289) 4289
venous thrombosis - drug therapy (4229) 4229
complications (4170) 4170
heparin - therapeutic use (4093) 4093
anticoagulants - administration & dosage (4065) 4065
recurrence (3973) 3973
child (3924) 3924
prognosis (3904) 3904
veins & arteries (3870) 3870
stent (3853) 3853
medicine, experimental (3849) 3849
pregnancy (3813) 3813
platelet aggregation inhibitors - therapeutic use (3796) 3796
tomography, x-ray computed (3776) 3776
pulmonary-embolism (3773) 3773
reports (3760) 3760
thrombosis - therapy (3753) 3753
risk assessment (3726) 3726
molecular-weight heparin (3697) 3697
incidence (3594) 3594
aspirin (3589) 3589
anticoagulants - adverse effects (3526) 3526
risk-factors (3524) 3524
clinical neurology (3474) 3474
blood clots (3390) 3390
oncology (3387) 3387
heart attacks (3372) 3372
warfarin (3362) 3362
thrombosis - diagnostic imaging (3338) 3338
medicine (3297) 3297
cardiovascular (3266) 3266
young adult (3227) 3227
radiology, nuclear medicine & medical imaging (3183) 3183
thrombosis - diagnosis (3152) 3152
anticoagulation (3127) 3127
pediatrics (3114) 3114
percutaneous coronary intervention (3072) 3072
cardiovascular diseases (3061) 3061
pharmacology & pharmacy (3021) 3021
cardiovascular disease (3010) 3010
venous thrombosis - diagnosis (2969) 2969
thrombosis - complications (2965) 2965
deep vein thrombosis (2956) 2956
thrombolysis (2915) 2915
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (155) 155
Online Resources - Online (49) 49
Collection Dvlpm't (Acquisitions) - Vendor file (21) 21
Collection Dvlpm't (Acquisitions) - Closed Orders (9) 9
UofT at Mississauga - Stacks (7) 7
Scarborough Hospital - General (4) 4
St. Michael's Hospital - Stacks (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Scarborough Hospital - Birchmount (3) 3
Credit Valley Hospital - Stacks (2) 2
Gerstein Science - Periodical Stacks (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Providence Healthcare - Stacks (2) 2
Toronto East General Hospital - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
Baycrest Hospital - Stacks (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Gerstein Science - Material is damaged (1) 1
Gerstein Science - Missing (1) 1
Humber River Regional Hospital - Church Reference (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Lakeridge Health Sciences - Online (1) 1
OISE - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Scarborough Hospital - Withdrawn (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's Hospital - Online (1) 1
St. Michael's Hospital - Reference (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
Trillium Health Centre - Stacks (1) 1
Women's College Hospital - Reference (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (104736) 104736
German (2984) 2984
French (2331) 2331
Japanese (975) 975
Spanish (925) 925
Russian (864) 864
Italian (501) 501
Chinese (408) 408
Polish (331) 331
Korean (173) 173
Dutch (136) 136
Portuguese (133) 133
Czech (130) 130
Danish (114) 114
Hungarian (106) 106
Swedish (94) 94
Turkish (83) 83
Norwegian (57) 57
Finnish (44) 44
Romanian (43) 43
Hebrew (34) 34
Croatian (26) 26
Bulgarian (23) 23
Serbian (22) 22
Ukrainian (20) 20
Slovak (16) 16
Slovenian (11) 11
Lithuanian (6) 6
Arabic (4) 4
Bosnian (4) 4
Icelandic (3) 3
Estonian (1) 1
Greek (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e326S - e350S
Background: This guideline addresses the management of patients who are receiving anticoagulant or antiplatelet therapy and require an elective surgery or... 
VITAMIN-K-ANTAGONISTS | PERCUTANEOUS CORONARY INTERVENTION | PROSTHETIC HEART-VALVES | LOW-DOSE ASPIRIN | RESPIRATORY SYSTEM | MOLECULAR-WEIGHT HEPARIN | ORAL ANTICOAGULANT-THERAPY | TRANEXAMIC ACID MOUTHWASH | NONVALVULAR ATRIAL-FIBRILLATION | INTERNATIONAL NORMALIZED RATIO | DRUG-ELUTING STENTS | CRITICAL CARE MEDICINE | Perioperative Care | United States | Humans | Postoperative Complications - blood | Postoperative Complications - prevention & control | Aspirin - pharmacokinetics | Angioplasty, Balloon, Coronary | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - pharmacokinetics | Postoperative Complications - drug therapy | Thrombosis - blood | Thrombosis - prevention & control | Stents | Platelet Aggregation Inhibitors - adverse effects | Drug Administration Schedule | Atrial Fibrillation - drug therapy | Heart Valve Prosthesis | Risk Factors | Atrial Fibrillation - complications | Evidence-Based Medicine | Atrial Fibrillation - blood | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Elective Surgical Procedures | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e152S - e184S
Background: High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This... 
COMPUTERIZED DECISION-SUPPORT | INTENSITY WARFARIN THERAPY | DEFINITE ANTIPHOSPHOLIPID SYNDROME | RESPIRATORY SYSTEM | PROTHROMBIN COMPLEX CONCENTRATE | MOLECULAR-WEIGHT HEPARIN | DEEP-VEIN THROMBOSIS | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | ACUTE VENOUS THROMBOEMBOLISM | ORAL VITAMIN-K | CRITICAL CARE MEDICINE | United States | Humans | Decision Support Systems, Clinical | Heparin - therapeutic use | Hemorrhage - prevention & control | Long-Term Care | Heparin - adverse effects | Heparin - pharmacokinetics | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Drug Interactions | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Drug-Related Side Effects and Adverse Reactions | Fibrinolytic Agents - therapeutic use | Thrombosis - blood | Thrombosis - prevention & control | Patient Education as Topic | Polysaccharides - therapeutic use | Drug Administration Schedule | Administration, Oral | Hemorrhage - therapy | Polysaccharides - adverse effects | Evidence-Based Medicine | Randomized Controlled Trials as Topic | International Normalized Ratio | Thrombosis - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Self Care | Polysaccharides - pharmacokinetics | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e44S - e88S
Background: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant... 
GAMMA-CARBOXYGLUTAMIC ACID | INTRAVENOUS PHYTONADIONE VITAMIN-K-1 | FACTOR-XA INHIBITOR | VENOUS LIMB GANGRENE | EUROPEAN CONCERTED ACTION | LOW-INTENSITY WARFARIN | RESPIRATORY SYSTEM | VITAMIN-K ANTAGONISTS | TOTAL HIP-REPLACEMENT | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | United States | Humans | Pyridines - pharmacokinetics | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacokinetics | Dose-Response Relationship, Drug | Rivaroxaban | Pyridines - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Benzimidazoles - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Morpholines - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Evidence-Based Medicine | Factor Xa - metabolism | Thiophenes - pharmacokinetics | Vitamin K - blood | Antithrombins - adverse effects | Anticoagulants - pharmacokinetics | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2016, Volume 68, Issue 10, pp. 1116 - 1139
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e419S - e496S
Background: This article addresses the treatment of VTE disease. Methods: We generated strong (Grade 1) and weak (Grade 2) recommendations based on... 
RIGHT-VENTRICULAR DYSFUNCTION | RECURRENT VENOUS THROMBOEMBOLISM | TISSUE-PLASMINOGEN-ACTIVATOR | RESPIRATORY SYSTEM | ACUTE PULMONARY-EMBOLISM | MOLECULAR-WEIGHT HEPARIN | VENA-CAVA FILTER | ORAL ANTICOAGULANT-THERAPY | INTRAVENOUS UNFRACTIONATED HEPARIN | LONG-TERM TREATMENT | DEEP-VEIN-THROMBOSIS | CRITICAL CARE MEDICINE | Venous Thrombosis - diagnosis | Pulmonary Embolism - prevention & control | United States | Humans | Venous Thrombosis - blood | Heparin, Low-Molecular-Weight - adverse effects | Hemorrhage - prevention & control | Long-Term Care | Heparin, Low-Molecular-Weight - therapeutic use | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - therapeutic use | Venous Thrombosis - prevention & control | Polysaccharides - therapeutic use | Drug Administration Schedule | Venous Thrombosis - drug therapy | Administration, Oral | Risk Factors | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Pulmonary Embolism - blood | International Normalized Ratio | Diagnostic Imaging | Pulmonary Embolism - diagnosis | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e669S - e690S
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e737S - e801S
Background: Neonates and children differ from adults in physiology, pharmacologic responses to drugs, epidemiology, and long-term consequences of thrombosis.... 
INFERIOR VENA-CAVA | TISSUE-PLASMINOGEN-ACTIVATOR | ARTERIAL ISCHEMIC-STROKE | RESPIRATORY SYSTEM | CEREBRAL SINOVENOUS THROMBOSIS | ACUTE LYMPHOBLASTIC-LEUKEMIA | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | HEPARIN-INDUCED THROMBOCYTOPENIA | SICKLE-CELL-DISEASE | HOMOZYGOUS PROTEIN-C | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Humans | Upper Extremity Deep Vein Thrombosis - blood | Child, Preschool | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Upper Extremity Deep Vein Thrombosis - prevention & control | Hemorrhage - prevention & control | Secondary Prevention | Heparin - adverse effects | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Cardiac Catheterization | Vitamin K - antagonists & inhibitors | Societies, Medical | Platelet Aggregation Inhibitors - administration & dosage | Renal Veins | Thrombosis - blood | Thrombosis - prevention & control | Child | Infant, Newborn | Platelet Aggregation Inhibitors - adverse effects | Upper Extremity Deep Vein Thrombosis - drug therapy | Drug Administration Schedule | Risk Factors | Cooperative Behavior | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Interdisciplinary Communication | Thrombosis - etiology | Blood Coagulation Tests | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e1S - e23S
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e531S - e575S
Background: The risk of stroke varies considerably across different groups of patients with atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is... 
DIRECT-CURRENT CARDIOVERSION | STROKE PREVENTION | RESPIRATORY SYSTEM | CLOPIDOGREL PLUS ASPIRIN | ORAL ANTICOAGULANT-THERAPY | RISK STRATIFICATION SCHEMES | MAJOR VASCULAR EVENTS | PULMONARY-VEIN ABLATION | ACUTE CORONARY SYNDROME | ECHOCARDIOGRAPHY-GUIDED CARDIOVERSION | ANTIARRHYTHMIC-DRUG THERAPY | CRITICAL CARE MEDICINE | Ticlopidine - therapeutic use | Humans | Electric Countershock | Hemorrhage - prevention & control | Dabigatran | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ticlopidine - adverse effects | Aspirin - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Stroke - prevention & control | beta-Alanine - adverse effects | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Atrial Fibrillation - blood | International Normalized Ratio | Stroke - blood | Atrial Flutter - complications | Atrial Flutter - drug therapy | Hemorrhage - chemically induced | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 11, pp. 1113 - 1121
Journal Article